Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times
International Business Times
Business

INSANE: Pfizer stock edges higher as oncology wins and pipeline bets fuel optimism amid flat 2026 outlook | Rare Historical Photos

NEW YORK — Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical giant's flat revenue guidance for 2026 and ongoing pressures from declining COVID-19 product sales.

Illustration shows Pfizer logo

Pfizer stock (NYSE: PFE) rose to around $27.97 in morning trading, up 20 cents or 0.72% from Monday's close near $27.77, with volume building as the market digested recent clinical successes and the company's long-term pivot toward oncology and obesity. The modest gain came after shares had traded in a relatively tight range in recent sessions, hovering near 52-week highs around $27.94.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.